| For: | Liu H, Zhang QD, Li ZH, Zhang QQ, Lu LG. Efficacy and safety of gemcitabine-based chemotherapies in biliary tract cancer: A meta-analysis. World J Gastroenterol 2014; 20(47): 18001-18012 [PMID: 25548500 DOI: 10.3748/wjg.v20.i47.18001] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v20/i47/18001.htm |
| Number | Citing Articles |
| 1 |
Subhajit Ghosh, Tapas Das, Haladhar D. Sarma, Ashutosh Dash. The potential of radiolabeled chemotherapeutics in tumor diagnosis: Preliminary investigations with 68Ga‐gemcitabine. Drug Development Research 2018; 79(3) doi: 10.1002/ddr.21423
|
| 2 |
Wei Li, Xiujun Song, Huijie Yu, Manze Zhang, Fengsheng Li, Cheng Cao, Qisheng Jiang. Dendritic cell-based cancer immunotherapy for pancreatic cancer. Arab Journal of Gastroenterology 2018; 19(1) doi: 10.1016/j.ajg.2017.05.013
|
| 3 |
Anand Singla, Richard A. Kozarek. Advanced Therapeutic Endoscopy for Pancreatico-Biliary Diseases. 2019; doi: 10.1007/978-4-431-56009-8_26
|
| 4 |
Teerachat Saeheng, Juntra Karbwang, Kesara Na-bangchang. Immunomodulatory Effects of Atractylodes lancea in Healthy Volunteers with Dosage Prediction for Cholangiocarcinoma Therapy: A Modelling Approach. Pharmaceuticals 2025; 18(2) doi: 10.3390/ph18020198
|
| 5 |
Syed Kashif Ali, Christy Thomas, Mahesh Rathod, Krishna Undela. Efficacy and safety of capecitabine therapy in patients with Biliary tract cancer: A systematic review and meta-analysis. Journal of Oncology Pharmacy Practice 2025; doi: 10.1177/10781552251372874
|
| 6 |
Meiqin Yuan, Wanxia Fang, Bixia Liu, Yahan Tong, Junchi Cheng, Haijun Zhong, Wangxia Lv. Preliminary Application of Toripalimab in Combination With GEMOX Regimen as a First-Line Treatment Option for Advanced Biliary Tract Tumors. British Journal of Hospital Medicine 2026; 87(1) doi: 10.31083/BJHM50279
|
| 7 |
Jason Ho, Steven A. Curley. Gastrointestinal Malignancies. Cancer Treatment and Research 2016; doi: 10.1007/978-3-319-34244-3_7
|
| 8 |
Omar Abdel-Rahman, Zeinab Elsayed, Hesham Elhalawani. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas. Cochrane Database of Systematic Reviews 2018; 2018(4) doi: 10.1002/14651858.CD011746.pub2
|
| 9 |
Aileen Deng, Steven Cohen. Primary and Metastatic Liver Tumors. 2018; doi: 10.1007/978-3-319-91977-5_11
|
| 10 |
Yaoqun Wang, Ningyuan Wen, Shaofeng Wang, Guilin Nie, Yuan Tian, Jiong Lu, Bei Li. Chemotherapy and targeted therapy for advanced biliary tract cancers: an umbrella review. BMC Cancer 2023; 23(1) doi: 10.1186/s12885-023-10679-8
|
| 11 |
Lars Henrik Jensen. Clinical aspects and perspectives of erlotinib in the treatment of patients with biliary tract cancer. Expert Opinion on Investigational Drugs 2016; 25(3) doi: 10.1517/13543784.2016.1142973
|
| 12 |
Wen-Kuan Huang, Chun-Nan Yeh. The Emerging Role of MicroRNAs in Regulating the Drug Response of Cholangiocarcinoma. Biomolecules 2020; 10(10) doi: 10.3390/biom10101396
|
| 13 |
Cheng Zhang, Ke Li, Shu-Ning Xu, Lei Qiao, Yu-Lin Ren, Qun Li, Ying Liu. A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) for gemcitabine. Expert Opinion on Drug Safety 2025; 24(3) doi: 10.1080/14740338.2024.2419999
|
| 14 |
Radu-Dumitru Dragomir, Marina Adriana Mercioni, Șerban Negru, Dorel Popovici, Sorin Săftescu, Andiana Roxana Blidari, Ioan Sas. Comparison of Hepatic Function and Chemotherapy-Induced Side Effects Between Pegylated Liposomal Doxorubicin (PLD), Topotecan (TOPO), and Gemcitabine in Platinum-Resistant Ovarian Cancer (PROC). Journal of Personalized Medicine 2025; 15(1) doi: 10.3390/jpm15010039
|
| 15 |
Van Khanh Nguyen, Hisashi Kosaka, Kosuke Matsui, Hideyuki Matsushima, Hidekazu Yamamoto, Gozo Kiguchi, Takuya Ohigashi, Thanh Tung Lai, Hoang Hai Duong, Kyoko Inoue, Moriyasu Takada, Hiroki Kato, Kengo Yoshii, Takashi Ito, Tsukasa Ikeura, Makoto Naganuma, Masaki Kaibori. Association Between Cumulative Chemotherapy Exposure and Survival Outcomes in Advanced Biliary Tract Cancer. Cancers 2026; 18(14) doi: 10.3390/cancers18142263
|